Not sure if this has already been posted but BTG released a...

Not sure if this has already been posted but BTG released a trading update on 6 April. In particular, the following extract is potentially of interest to SRX s/holders:

"Our business has performed well this year. We have made significant progress in executing our strategy to become a leading provider of Interventional Medicine therapies. We have expanded the portfolio both organically and through acquisition and have delivered good revenue growth. A strong performance from TheraSphere® and the addition of Galil Medical have helped cement our leadership in Interventional Oncology. EKOS has continued to increase market penetration, and we have achieved important milestones in our earlier stage businesses. There is good momentum across our business and we start the new financial year with confidence."

It seems that unlike SRX, BTG is not encountering a slowdown in sales of SIRT. This could be due to various factors but I have a nagging suspicion that BTG's increasingly diversified interventional oncology business represents a strengthening competitive advantage over SRX.